Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ALK/TRK Inhibitor TSR-011

Known as: TSR-011 
An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers in non-small-cell lung cancer (NSCLC). TSR-011 is a… Expand
  • table 2
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?
2019
2019
Belizatinib (BZB; TSR-011) is a next-generation anaplastic lymphoma kinase inhibitor that also inhibits tropomyosin-related… Expand
Is this relevant?
Review
2017
Review
2017
&NA; The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins, which are encoded by NTRK1, NTRK2 and… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
Review
2016
Review
2016
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK… Expand
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2015
2015
8063 Background: Both intrinsic and acquired resistance mechanisms to ALK inhibitors have been observed in ALK rearranged (ALK… Expand
Is this relevant?
Review
2015
Review
2015
AbstractThe therapeutic targeting of anaplastic lymphoma kinase (ALK) has been a burgeoning area of research since 2007 when ALK… Expand
Is this relevant?
Review
2015
Review
2015
  • Georg Pall
  • Current opinion in oncology
  • 2015
  • Corpus ID: 25506552
Purpose of review Crizotinib now is accepted as the standard first-line treatment of ALK-rearranged lung adenocarcinomas. To… Expand
Is this relevant?
2014
2014
e19005 Background: Ultimately, the majority of anaplastic lymphoma kinase (ALK) rearranged (+) non-small cell lung cancers (NSCLC… Expand
Is this relevant?
2014
2014
Background: Both intrinsic and acquired resistance mechanisms to ALK inhibitors have been observed in ALK rearranged (ALK+) non… Expand
Is this relevant?
Review
2014
Review
2014
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?